Company Profile
Artivion Stock Price, News & Analysis
Company overview
Business overview
Artivion is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NYSE, Artivion is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Artivion follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Artivion sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
AORT is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Artivion's catalysts are On-X valve execution, AMDS progress, and continued aortic-repair adoption. The next update matters if it shows the procedural base is still gaining traction.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
- 03
Artivion to Participate in the Stifel 2025 Healthcare Conference
Source: Artivion
- 04
- 05
Artivion Reports Third Quarter 2025 Financial Results
Source: Artivion
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.